Log in

NYSE:DPLO - Diplomat Pharmacy Stock Price, Forecast & News

$4.00
0.00 (0.00 %)
(As of 02/27/2020 01:02 AM ET)
Today's Range
$4.00
Now: $4.00
$4.00
50-Day Range
$3.98
MA: $4.00
$4.10
52-Week Range
$2.43
Now: $4.00
$14.46
VolumeN/A
Average Volume545,194 shs
Market Capitalization$304 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.60 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$304 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($0.20) by $2.15. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. The company's revenue was down 5.3% on a year-over-year basis. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Diplomat Pharmacy.

What price target have analysts set for DPLO?

10 analysts have issued 12 month price objectives for Diplomat Pharmacy's stock. Their forecasts range from $3.00 to $8.00. On average, they expect Diplomat Pharmacy's share price to reach $5.78 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

News stories about DPLO stock have been trending somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Diplomat Pharmacy.

Are investors shorting Diplomat Pharmacy?

Diplomat Pharmacy saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,980,000 shares, a decline of 30.5% from the January 15th total of 4,290,000 shares. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is currently 1.3 days. Approximately 5.2% of the company's shares are short sold. View Diplomat Pharmacy's Current Options Chain.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Ford Motor (F), Cara Therapeutics (CARA), CVS Health (CVS), General Motors (GM), Activision Blizzard (ATVI), Exelixis (EXEL) and Horizon Therapeutics (HZNP).

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.36%), State Street Corp (2.69%), Charles Schwab Investment Management Inc. (1.83%), Geode Capital Management LLC (1.01%), Water Island Capital LLC (0.93%) and Bank of New York Mellon Corp (0.86%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which major investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Cambridge Investment Research Advisors Inc., Citigroup Inc., Arizona State Retirement System, Prudential Financial Inc., New York State Common Retirement Fund, Public Sector Pension Investment Board and State of Tennessee Treasury Department. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Regina M Benjamin. View Insider Buying and Selling for Diplomat Pharmacy.

Which major investors are buying Diplomat Pharmacy stock?

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Water Island Capital LLC, Gabelli Funds LLC, Dupont Capital Management Corp, Barclays PLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $4.00.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $304 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  392 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel